Sino Biopharmaceutical Limited reported that, as of 28 February 2026, the authorized share capital remained at 30.00 billion ordinary shares with a par value of HKD 0.025 each, totaling HKD 750.00 million. The issued share capital stood at 18.76 billion shares, showing no change during the reporting month. The company confirmed compliance with the 25% public float requirement.

An agreement was previously signed in January 2026 for the acquisition of 100% equity interest in Hangzhou Hygieia Biomedical Co., Ltd., partly settled through an allotment of 14.60 million shares. As of February 2026, no new shares have been issued under this agreement, and the total number of treasury shares also remained unchanged.